Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AGEE 623; AGEE 623 ZW; GlucoNorm; NN 623; NovoNorm; Prandin; SMP 508; Surepost

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Novo Nordisk; Sumitomo Dainippon Pharma
  • Class Antihyperglycaemics; Carbamates; Piperidines; Small molecules
  • Mechanism of Action Insulinotropin agonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 18 Nov 2014 Launched for Type-2 diabetes mellitus (Combination therapy) in Japan (PO)
  • 18 Nov 2014 Sumitomo Dainippon Pharma receives approval in Japan for partial change of the approved indications to include the use of repaglinide in combination with any oral hypoglycaemic agents, except with sulfonylurea and insulin formulations
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top